Latest / Community Health Media
Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability
How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer?
In this CHM Conversations episode, Drs. Neil Iyengar, Manali Bhave, and Reshma Mahtani explore the shifting second-line landscape for HR+/HER2- metastatic breast cancer. The discussion centers on the clinical integration of capivasertib and the necessity of biomarker testing—specifically PIK3CA, AKT, PTEN, and ESR1—following progression on CDK4/6 inhibitors.
The panel emphasizes a proactive approach to toxicity, detailing how multidisciplinary care and early metabolic optimization can mitigate…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.